At a Glance
| Feature | Detail |
|---|---|
| Condition | Multiple Sclerosis (MS) |
| ICD-10 Code | G35 |
| CDL Status | YES — Chronic Disease List (CDL 021) |
| PMB Coverage | Disease-modifying therapy funded — but WHICH DMT depends entirely on scheme formulary |
| SA Prevalence | ~3,000–5,000 people; whites 25.63/100,000; Black Africans 0.22/100,000 |
| Standard Treatment | Disease-modifying therapy (DMT) — class chosen based on MS type and activity level |
| Annual DMT Cost Range | R54,000 (interferon beta) to R250,000+ (ocrelizumab) |
| Biologic Risk | YES — ocrelizumab is the most expensive medication in the Phase 1a AURA condition set |
| Key Advisory Angle | MS is a SCHEME decision, not a plan decision. Which DMT your scheme will fund determines your clinical and financial outcome. |
About Multiple Sclerosis
Multiple sclerosis is a chronic autoimmune disease in which the immune system attacks myelin — the protective sheath around nerve fibres in the brain, spinal cord, and optic nerves. Demyelination slows or blocks nerve signal transmission, producing the wide variety of neurological symptoms that characterise MS.
MS is the most expensive condition to treat in the AURA Phase 1a condition set when high-efficacy therapy is required. The drug ocrelizumab (Ocrevus) — currently the only approved treatment for primary progressive MS and increasingly used for relapsing-remitting MS — costs an estimated R180,000–R250,000/year in South Africa.
South Africa has approximately 3,000–5,000 people living with MS, with dramatically unequal prevalence across population groups. The disease is historically underdiagnosed in Black Africans, where true prevalence may be higher than the 0.22/100,000 rate suggests.
Types of MS
| Type | Description | Proportion |
|---|---|---|
| Relapsing-Remitting MS (RRMS) | Discrete attacks (relapses) with full or partial recovery between episodes. Most common type at diagnosis (~85%). | ~85% at onset |
| Secondary Progressive MS (SPMS) | RRMS that transitions to gradual progressive worsening, with or without relapses. | Most RRMS eventually transitions |
| Primary Progressive MS (PPMS) | Progressive disability from onset, without early relapses. ~15% of MS. Ocrelizumab is the only approved treatment. | ~15% |
| Clinically Isolated Syndrome (CIS) | First episode of demyelination — may or may not progress to MS. Early DMT initiation after CIS reduces conversion to MS. | N/A |
Diagnosis
MS diagnosis requires clinical evidence (history + examination), MRI evidence (brain + spinal cord lesions), and exclusion of alternative diagnoses. The McDonald Criteria (2017) provide the diagnostic standard.
Key diagnostic investigations: - MRI brain and spinal cord with gadolinium contrast — the cornerstone. Lesions disseminated in space and time confirm MS. - Lumbar puncture (CSF analysis) — oligoclonal bands in CSF support MS diagnosis - Visual evoked potentials — detect subclinical optic nerve damage - Blood tests — rule out differential diagnoses (vitamin B12 deficiency, lupus, neuromyelitis optica/NMOSD)
Treatment: Disease-Modifying Therapies (DMTs)
Platform Therapies (First-Line, Older)
Reduce relapse rate by 30–50%. Injectable (SC or IM). - Interferon beta-1a (Rebif 44mcg 3×/week or Avonex 30mcg weekly) — ~R4,500/month → ~R54,000/year - Interferon beta-1b (Betaferon 250mcg every other day) — ~R4,000/month → ~R48,000/year - Glatiramer acetate (Copaxone 20mg daily) — ~R4,200/month → ~R50,400/year
Oral DMTs (Moderate-to-High Efficacy)
- Fingolimod (Gilenya / generic) 0.5mg daily — S1P modulator. ~R4,000/month → ~R48,000/year. First-dose cardiac monitoring required.
- Dimethyl fumarate (Tecfidera / generic) 240mg twice daily — ~R3,500/month → ~R42,000/year
High-Efficacy Biologics (Monoclonal Antibodies)
- Ocrelizumab (Ocrevus — Roche) 600mg IV every 6 months. Only approved treatment for PPMS. Increasingly first-line for highly active RRMS. Estimated ~R180,000–R250,000/year. SAHPRA-approved.
- Natalizumab (Tysabri) 300mg IV monthly. Requires JC virus monitoring (PML risk). ~R108,000/year (estimate).
- Alemtuzumab (Lemtrada) — infusion pulse therapy, 2 years. High efficacy, significant toxicity. ~R280,000/year for infusion courses (estimate).
Oral High-Efficacy
- Cladribine (Mavenclad) — oral pulse (4–5 days × 2 courses over 2 years). ~R150,000/year for treatment years. No treatment required for up to 4 subsequent years.
Annual Cost Estimates
| Severity | Profile | Estimated Annual Cost |
|---|---|---|
| Mild RRMS | Interferon beta, annual neurology, brain MRI | ~R62,800 |
| Moderate RRMS | Fingolimod, quarterly neurology, annual MRI | ~R61,600 |
| Severe RRMS or PPMS | Ocrelizumab, quarterly neurology, annual MRI | R202,600–R272,600 |
The PMB and CDL Position
MS is a CDL condition. Schemes must fund neurologist consultations and disease-modifying therapy as per the CDL algorithm.
Critical distinction: The CDL requires that DMT be funded, but it does not specify WHICH DMT at the high-efficacy tier. Platform therapies (interferon beta, glatiramer acetate) are typically covered as CDL first-line. High-efficacy biologics (ocrelizumab, natalizumab, alemtuzumab) require exceptional needs authorisation — and scheme policy determines whether they fund these.
The result: A patient needing ocrelizumab for PPMS on one scheme may receive full funding. On another scheme, the same patient may face an R180,000–R250,000/year out-of-pocket burden. This is why MS is definitively a SCHEME decision.
Gap Cover Relevance
| Scenario | Gap Cover Relevance |
|---|---|
| Routine DMT (interferon beta, oral) | LOW — CDL-funded; little gap exposure on the medicine |
| High-efficacy DMT OOP cost | NONE — gap cover does not cover formulary exclusions |
| Acute relapse: IV methylprednisolone admission | MEDIUM — neurologist shortfall |
| Ocrelizumab infusion reaction (day case) | LOW — typically managed as day case |
| Physiotherapy and OT for disability management | LOW — typically d2d benefits |
The Talk to Eldon Angle
For any person with MS considering their scheme, the primary question is: does this scheme have an exceptional needs pathway that will fund ocrelizumab if my neurologist requires it? This overrides plan selection, plan comparison, and gap cover selection. Choose the right scheme. The plan follows.
For patients on platform therapies with stable, low-activity RRMS, the scheme choice is less acute — most schemes fund interferons and glatiramer acetate.
Sources
- South Africa's silent struggle with multiple sclerosis. Thisability, May 2024.
- Multiple Sclerosis in sub-Saharan Africa — scoping review. ScienceDirect, 2020.
- Multiple sclerosis in South Africa. SAMJ, 2008.
- SAHPRA Medicines Registration Portal — Ocrelizumab.
- Medical Aid Schemes that Cover MS. MedicalAid.co.za, 2024.
- CMS PMB Regulations — CDL: Multiple Sclerosis.
Ready to check your MS cover? Run your AURA medical aid check